Joshua F Zeidner

Trials

Studies that name Joshua F Zeidner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:26 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04802161 · Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

  National Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia · principal investigator
• Ph2
  NCT02768792 · High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

  UNC Lineberger Comprehensive Cancer Center · completed · Acute Myeloid Leukemia, in Relapse · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
  UM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026
  Named on NCT04802161